Scarica l'app Stockscreener
52.02
6.27%
3.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$48.95
Aprire:
$48.72
Volume 24 ore:
3.97M
Relative Volume:
1.96
Capitalizzazione di mercato:
$6.41B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
17.23
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-21.03%
1M Prestazione:
-11.56%
6M Prestazione:
+13.95%
1 anno Prestazione:
+14.61%
Intervallo 1D:
$48.64
$52.75
Intervallo di 1 settimana:
$47.50
$67.90
Portata 52W:
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
52.02 | 8.12B | 947.36M | 392.47M | 392.71M | 3.02 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Halozyme downgraded at Morgan Stanley on price control risk - MSN
Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance
Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World
Morgan Stanley Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq
Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance
Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus
Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow
Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance
Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus
Halozyme stock holds $78 target despite Medicare concerns - Investing.com
Morgan Stanley cuts Halozyme stock rating, lowers target By Investing.com - Investing.com Nigeria
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - MSN
Halozyme at BofA Securities Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
Transcript : Halozyme Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
Evercore ISI maintains Outperform on Halozyme amid CMS draft By Investing.com - Investing.com Canada
Halozyme at BofA Securities Conference: Strategic Growth Insights - Investing.com Australia
Halozyme stock rating cut to Underperform at Leerink Partners By Investing.com - Investing.com Nigeria
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News - Investor's Business Daily
Evercore ISI maintains Outperform on Halozyme amid CMS draft - Investing.com
Halozyme Shares Fall After Leerink Partners Downgrade - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Halozyme Therapeutics (HALO) Downgraded Amid Medicare Negotiatio - GuruFocus
Halozyme (HALO) Stock Downgraded Amid Concerns Over CMS Guidance - GuruFocus
J&J stock Halozyme stock cut at Leerink Partners (JNJ:NYSE) - Seeking Alpha
Halozyme stock rating cut to Underperform at Leerink Partners - Investing.com
Halozyme (HALO) Faces Downgrade Amid Potential Revenue Risks | H - GuruFocus
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Leerink Partners Downgrades Halozyme Therapeutics to Underperform From Market Perform, Price Target is $47 - marketscreener.com
Halozyme shares tumble on downgrade and CMS draft guidance By Investing.com - Investing.com Canada
Halozyme shares tumble on downgrade and CMS draft guidance - Investing.com
Halozyme Therapeutics downgraded by Leerink Partners with a new price target - Quantisnow
Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now? - Insider Monkey
(HALO) Technical Data - news.stocktradersdaily.com
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat (NASDAQ:HALO) - Seeking Alpha
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Cut to Hold at Benchmark - Defense World
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates - MSN
Halozyme sees strong Q1 2025 growth, raises 2025 revenue guidance to $1.2B-$1.28B - MSN
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View - MSN
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - NewsBreak: Local News & Alerts
Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Halozyme Therapeutics Inc Azioni (HALO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | Director |
Apr 01 '25 |
Sale |
64.05 |
503 |
32,217 |
33,108 |
| Henderson Jeffrey William | Director |
Mar 03 '25 |
Sale |
58.69 |
5,000 |
293,458 |
33,611 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 26 '25 |
Sale |
58.12 |
10,000 |
581,244 |
175,453 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 25 '25 |
Sale |
58.05 |
10,000 |
580,534 |
185,453 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 27 '25 |
Sale |
58.28 |
1,697 |
98,902 |
173,756 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):